NASDAQ:PCRX - Pacira Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$38.05 +0.85 (+2.28 %)
(As of 06/20/2018 03:19 AM ET)
Previous Close$38.05
Today's Range$36.55 - $38.15
52-Week Range$26.95 - $51.10
Volume507,702 shs
Average Volume973,512 shs
Market Capitalization$1.53 billion
P/E Ratio-65.60
Dividend YieldN/A
Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio1.00
Current Ratio8.66
Quick Ratio7.83


Trailing P/E Ratio-65.60
Forward P/E Ratio-66.75
P/E GrowthN/A

Sales & Book Value

Annual Sales$286.63 million
Price / Sales5.41
Cash Flow$0.0621 per share
Price / Cash612.95
Book Value$6.89 per share
Price / Book5.52


EPS (Most Recent Fiscal Year)($0.58)
Net Income$-42,610,000.00
Net Margins-11.45%
Return on Equity-5.81%
Return on Assets-2.56%


Outstanding Shares40,730,000

Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) issued its quarterly earnings data on Thursday, May, 3rd. The company reported $0.02 earnings per share for the quarter, meeting analysts' consensus estimates of $0.02. The firm earned $74.61 million during the quarter, compared to analyst estimates of $73.92 million. Pacira Pharmaceuticals had a negative return on equity of 5.81% and a negative net margin of 11.45%. Pacira Pharmaceuticals's quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.19) EPS. View Pacira Pharmaceuticals' Earnings History.

When is Pacira Pharmaceuticals' next earnings date?

Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacira Pharmaceuticals.

What price target have analysts set for PCRX?

21 analysts have issued 1-year price objectives for Pacira Pharmaceuticals' stock. Their predictions range from $27.00 to $80.00. On average, they expect Pacira Pharmaceuticals' share price to reach $45.1765 in the next twelve months. View Analyst Ratings for Pacira Pharmaceuticals.

What are Wall Street analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:
  • 1. Mizuho analysts commented, "We note that consensus estimates are already toward the top end of the range and investors may have been hoping for a slight guidance raise after mgmt.’s optimistic remarks about rapid uptake of the nerve block utilization amongst anesthesiologists. Pacira remains a challenging stock because of the uncertainty around the takeout thesis in the name, and the overhang from Heron’s pending data releases and launch. We reiterate our Neutral rating." (5/3/2018)
  • 2. According to Zacks Investment Research, "Pacira fourth-quarter 2017 earnings surpassed estimates while revenues were at par with them. Pacira’s top line mainly comprises contribution from its marketed product Exparel which generated sales of $282.9 million in 2017, up 6.4%. The company’s efforts to expand Exparel's label are encouraging. Pacira remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. However, the company is heavily dependent on Exparel for growth. In February 2018, the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee reviewed the company’s sNDA, and voted six to four against approval of the expanded indication. We believe that this is a concern for the company. However, the company however remains confident and will keep an open dialogue with the FDA to define the best next steps for expanding the Exparel indication." (3/6/2018)
  • 3. Canaccord Genuity analysts commented, "We’re looking for more than two months of data showing solid growth before we become positive on the potential for a meaningful inflection in Exparel use trends, especially with a noisy October that may have benefited from hurricane-related deferred procedures that negatively impacted September volumes. We remain HOLD rated on PCRX shares." (12/29/2017)
  • 4. Cowen Inc analysts commented, "Nerve block data for Exparel is anticipated within the next month, and our consultants." (7/14/2017)

Who are some of Pacira Pharmaceuticals' key competitors?

Who are Pacira Pharmaceuticals' key executives?

Pacira Pharmaceuticals' management team includes the folowing people:
  • Mr. David M. Stack, Chairman and Chief Exec. Officer (Age 68)
  • Mr. Charles A. Reinhart III, Chief Financial Officer (Age 57)
  • Ms. Kristen Williams J.D., Chief Admin. Officer, Gen. Counsel and Sec. (Age 44)
  • Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 39)
  • Dr. Richard Scranton M.D., MPH, Chief Scientific Officer

Has Pacira Pharmaceuticals been receiving favorable news coverage?

News stories about PCRX stock have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacira Pharmaceuticals earned a news sentiment score of 0.22 on Accern's scale. They also gave news coverage about the company an impact score of 44.90 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Pacira Pharmaceuticals' major shareholders?

Pacira Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.93%), PARTNER FUND MANAGEMENT, L.P. (6.00%), PointState Capital LP (5.00%), venBio Select Advisor LLC (4.21%), Schroder Investment Management Group (3.01%) and Stephens Investment Management Group LLC (2.58%). Company insiders that own Pacira Pharmaceuticals stock include Charles A Reinhart III, David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings, Richard Scranton and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Which major investors are selling Pacira Pharmaceuticals stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Westfield Capital Management Co. LP, JPMorgan Chase & Co., Tamarack Advisers LP, Mesirow Financial Investment Management Equity Management, Highbridge Capital Management LLC, Eaton Vance Management and Oak Ridge Investments LLC. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include Charles A Reinhart III, David M Stack, James B Jones, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Pharmaceuticals.

Which major investors are buying Pacira Pharmaceuticals stock?

PCRX stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, PointState Capital LP, Nexthera Capital LP, Summit Trail Advisors LLC, Millennium Management LLC, Elk Creek Partners LLC, Schroder Investment Management Group and Baillie Gifford & Co.. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Mark A Kronenfeld and Mark Froimson. View Insider Buying and Selling for Pacira Pharmaceuticals.

How do I buy shares of Pacira Pharmaceuticals?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacira Pharmaceuticals' stock price today?

One share of PCRX stock can currently be purchased for approximately $38.05.

How big of a company is Pacira Pharmaceuticals?

Pacira Pharmaceuticals has a market capitalization of $1.53 billion and generates $286.63 million in revenue each year. The company earns $-42,610,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Pacira Pharmaceuticals employs 489 workers across the globe.

How can I contact Pacira Pharmaceuticals?

Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]

MarketBeat Community Rating for Pacira Pharmaceuticals (PCRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  575 (Vote Outperform)
Underperform Votes:  347 (Vote Underperform)
Total Votes:  922
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.